nach oben

Erschienen in:

02.04.2024 | ORIGINAL ARTICLE

Frequency and the effects of spondyloarthritis-spectrum disorders on the clinical course and management of Takayasu arteritis: an observational retrospective study

verfasst von: Kerem Abacar, Sema Kaymaz-Tahra, Özün Bayındır, Burak İnce, Muhammet Emin Kutu, Ayten Yazıcı, Elif Durak Ediboğlu, Tuba Demirci-Yıldırım, Zeliha Ademoğlu, Ahmet Omma, Nazife Şule Yaşar-Bilge, Gezmiş Kimyon, Timuçin Kaşifoğlu, Hakan Emmungil, Fatoş Önen, Servet Akar, Ayşe Cefle, Nilüfer Alpay-Kanıtez, Selda Çelik, Murat İnanç, Kenan Aksu, Gökhan Keser, Haner Direskeneli, Fatma Alibaz-Öner

Erschienen in: Clinical Rheumatology | Ausgabe 5/2024

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Extravascular findings of Takayasu arteritis (TAK) often share features with the spondyloarthritis (SpA) spectrum of disorders. However, the characteristics of this overlap and its effect on the vascular manifestations of TAK are not fully known. Therefore, we aimed to investigate the frequency of SpA-related features in TAK patients.

Material and methods

In this observational retrospective study, 350 patients with TAK classified according to ACR 1990 criteria, from 12 tertiary rheumatology clinics, were included and evaluated for the presence of axSpA, IBD, or psoriasis. Demographic, clinical features, angiographic involvement patterns, disease activity, and treatments of TAK patients with or without SpA were analyzed.

Results

Mean age was 45.5 ± 13.6 years and mean follow-up period was 76.1 ± 65.9 months. Among 350 patients, 31 (8.8%) had at least one additional disease from the SpA spectrum, 8 had IBD, 8 had psoriasis, and 20 had features of axSpA. In the TAK-SpA group, TAK had significantly earlier disease onset, compared to TAK-without-SpA (p = 0.041). SpA-related symptoms generally preceded TAK symptoms. Biological treatments, mostly for active vasculitis, were higher in the TAK-SpA group (70.9%) compared to TAK-without-SpA (27.9%) (p < 0.001). Vascular involvements were similar in both.

Conclusion

Our study confirmed that diseases in the SpA spectrum are not rare in TAK. Vascular symptoms appeared earlier in such patients, and more aggressive therapy with biological agents was required in the TAK-SpA group, suggesting an association between TAK and SpA spectrum.

Key Points

• The pathogenesis of Takayasu arteritis is mediated by an MHC class I alelle (HLA-B*52), similar to spondyloarthritis-disorders.

• Extravascular findings of Takayasu arteritis are in the spectrum of spondyloarthritis disease.

• This frequent coexistence between Takayasu arteritis and spondyloarthritic disorders suggests a relationship rather than a coincidence.

Alibaz-Oner F, Aydin SZ, Direskeneli H (2013) Advances in the diagnosis, assessment and outcome of Takayasu’s arteritis. Clin Rheumatol. 32(5):541–6. https://doi.org/10.1007/s10067-012-2149-3CrossRefPubMed

Yilmaz N, Can M, Oner FA, Kalfa M, Emmungil H, Karadag O et al (2013) Impaired quality of life, disability and mental health in Takayasu’s arteritis. Rheumatology (Oxford). 52(10):1898–904. https://doi.org/10.1093/rheumatology/ket238CrossRefPubMed

Renauer P, Sawalha AH (2017) The genetics of Takayasu arteritis. La Presse Méd 46(7–8):e179–e187CrossRef

Sahin Z, Bıcakcıgil M, Aksu K, Kamali S, Akar S, Onen F et al (2012) Takayasu’s arteritis is associated with HLA-B* 52, but not with HLA-B* 51, in Turkey. Arthritis Res Ther 14(1):1–5CrossRef

Saruhan-Direskeneli G, Hughes T, Aksu K, Keser G, Coit P, Aydin SZ et al (2013) Identification of multiple genetic susceptibility loci in Takayasu arteritis. Am J Hum Genet 93(2):298–305CrossRefPubMedPubMedCentral

Terao C, Yoshifuji H, Kimura A, Matsumura T, Ohmura K, Takahashi M et al (2013) Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. Am J Hum Genet 93(2):289–297CrossRefPubMedPubMedCentral

Carmona FD, Coit P, Saruhan-Direskeneli G, Hernandez-Rodriguez J, Cid MC, Solans R et al (2017) Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Sci Rep. 7:43953. https://doi.org/10.1038/srep43953CrossRefPubMedPubMedCentral

Ortiz-Fernandez L, Saruhan-Direskeneli G, Alibaz-Oner F, Kaymaz-Tahra S, Coit P, Kong X et al (2021) Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. Am J Hum Genet. 108(1):84–99. https://doi.org/10.1016/j.ajhg.2020.11.014CrossRefPubMed

Keser G, Aksu K, Direskeneli RH (2018) Takayasu arteritis: an update. Turk J Med Sci. 48(4):681–97CrossRefPubMed

10.

Paloheimo JA, Julkunen H, Siltanen P, Kajander A (1966) Takayasu’s arteritis and ankylosing spondylitis. Report of four cases. Acta Med Scand 179(1):77–85. https://doi.org/10.1111/j.0954-6820.1966.tb05435.xCrossRefPubMed

11.

Ghozlan R, Amor B, Delbarre F (1977) Association of Takayasu disease and ankylosing spondylarthritis: a further case. Ann Med Interne (Paris) 128(12):959–963PubMed

12.

Owyang C, Miller LJ, Lie JT, Fleming CR (1979) Takayasu’s arteritis in Crohn’s disease. Gastroenterology 76(4):825–828CrossRefPubMed

13.

Friedman CJ, Tegtmeyer CJ (1979) Crohn’s disease associated with Takayasu’s arteritis. Dig Dis Sci. 24(12):954–8. https://doi.org/10.1007/bf01311953CrossRefPubMed

14.

Terao C, Matsumura T, Yoshifuji H, Kirino Y, Maejima Y, Nakaoka Y et al (2015) Takayasu arteritis and ulcerative colitis: high rate of co-occurrence and genetic overlap. Arthritis Rheumatol 67(8):2226–2232. https://doi.org/10.1002/art.39157CrossRefPubMed

15.

Esatoglu SN, Ok AM, Ucar D, Celik AF, Ugurlu S, Hamuryudan V et al (2020) Takayasu’s arteritis: associated inflammatory diseases. Clin Exp Rheumatol. 38(Suppl 124(2)):61–8PubMed

16.

Kwon OC, Lee SW, Park YB, Oh JS, Lee SH, Hong S et al (2018) Extravascular manifestations of Takayasu arteritis: focusing on the features shared with spondyloarthritis. Arthritis Res Ther. 20(1):142. https://doi.org/10.1186/s13075-018-1643-7CrossRefPubMedPubMedCentral

17.

Gan FY, Fei YY, Li MT, Wang Q, Xu D, Hou Y et al (2014) The characteristics of patients having ankylosing spondylitis associated with Takayasu’s arteritis. Clin Rheumatol. 33(3):355–8. https://doi.org/10.1007/s10067-013-2444-7CrossRefPubMed

18.

McGonagle D, Aydin SZ, Gul A, Mahr A, Direskeneli H (2015) ‘MHC-I-opathy’-unified concept for spondyloarthritis and Behcet disease. Nat Rev Rheumatol. 11(12):731–40. https://doi.org/10.1038/nrrheum.2015.147CrossRefPubMed

19.

Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33(8):1129–1134CrossRefPubMed

20.

Hata A, Noda M, Moriwaki R, Numano F (1996) Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol 54:S155–S163CrossRefPubMed

21.

Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM et al (2013) Development and initial validation of the Indian Takayasu clinical activity score (ITAS2010). Rheumatology 52(10):1795–1801CrossRefPubMed

22.

Exley A, Bacon P, Luqmani R, Kitas G, Gordon C, Savage C et al (1997) Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40(2):371–380CrossRefPubMed

23.

Mv Rudwaleit, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou C et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25–31CrossRef

24.

Tillett W, Costa L, Jadon D, Wallis D, Cavill C, McHUGH J et al (2012) The ClASsification for Psoriatic ARthritis (CASPAR) criteria—a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 39(1):154–156CrossRefPubMed

25.

Linden SVD, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum 27(4):361–368CrossRefPubMed

26.

Rudwaleit M, Jurik A-G, Hermann KA, Landewé R, van der Heijde D, Baraliakos X et al (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68(10):1520–1527CrossRefPubMed

27.

Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMed

28.

Calin A, Garrett S, Whitelock H, Kennedy LG, O’hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 21(12):2281–5PubMed

29.

Riviere E, Arnaud L, Ebbo M, Allanore Y, Claudepierre P, Dernis E et al (2017) Takayasu arteritis and spondyloarthritis: coincidence or association? A study of 14 cases. J Rheumatol. 44(7):1011–7. https://doi.org/10.3899/jrheum.160762CrossRefPubMed

30.

Güzel Esen S, Armagan B, Atas N, Ucar M, Varan Ö, Erden A et al (2019) Increased incidence of spondyloarthropathies in patients with Takayasu arteritis: a systematic clinical survey. Joint Bone Spine 86(4):497–501. https://doi.org/10.1016/j.jbspin.2019.01.020CrossRefPubMed

31.

Michelena X, Lopez-Medina C, Erra A, Juanola X, Font-Ugalde P, Collantes E, et al. Characterising the axial phenotype of psoriatic arthritis: a study comparing axial psoriatic arthritis and ankylosing spondylitis with psoriasis from the REGISPONSER registry. RMD Open. 2022;8(2). https://doi.org/10.1136/rmdopen-2022-002513

32.

Sahin Z, Bicakcigil M, Aksu K, Kamali S, Akar S, Onen F et al (2012) Takayasu’s arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey. Arthritis Res Ther. 14(1):R27. https://doi.org/10.1186/ar3730CrossRefPubMedPubMedCentral

33.

Wong RH, Wei JC, Huang CH, Lee HS, Chiou SY, Lin SH et al (2012) Association of IL-12B genetic polymorphism with the susceptibility and disease severity of ankylosing spondylitis. J Rheumatol. 39(1):135–40. https://doi.org/10.3899/jrheum.110613CrossRefPubMed

34.

Martinez-Barricarte R, Markle JG, Ma CS, Deenick EK, Ramirez-Alejo N, Mele F, et al. Human IFN-gamma immunity to mycobacteria is governed by both IL-12 and IL-23. Sci Immunol. 2018;3(30). https://doi.org/10.1126/sciimmunol.aau6759

Titel: Frequency and the effects of spondyloarthritis-spectrum disorders on the clinical course and management of Takayasu arteritis: an observational retrospective study
verfasst von: Kerem Abacar
Sema Kaymaz-Tahra
Özün Bayındır
Burak İnce
Muhammet Emin Kutu
Ayten Yazıcı
Elif Durak Ediboğlu
Tuba Demirci-Yıldırım
Zeliha Ademoğlu
Ahmet Omma
Nazife Şule Yaşar-Bilge
Gezmiş Kimyon
Timuçin Kaşifoğlu
Hakan Emmungil
Fatoş Önen
Servet Akar
Ayşe Cefle
Nilüfer Alpay-Kanıtez
Selda Çelik
Murat İnanç
Kenan Aksu
Gökhan Keser
Haner Direskeneli
Fatma Alibaz-Öner
Publikationsdatum: 02.04.2024
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 5/2024
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-024-06939-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Objectives

Material and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2024

Evaluation of the prognostic nutritional index (PNI) as a tool for assessing disease activity in rheumatoid arthritis patients

Respiratory infection risk in primary Sjögren’s syndrome complicated with interstitial lung disease: a retrospective study

Increased carotid intima-media thickness in patients with radiographic axial spondyloarthritis compared to controls and associations with markers of inflammation

Coffee intake reduced gout risk by decreasing urate and urea while increasing SHBG levels in plasma: a mediation Mendelian randomization study

Anti-tumor necrosis factor (aTNF) weaning strategy in juvenile idiopathic arthritis (JIA): does duration matter?